2024-11-09 - Analysis Report
## PFE (Pfizer Inc.) Stock Analysis Report 

**Company Overview:** Pfizer Inc. is a global pharmaceutical company that researches, develops, manufactures, and markets drugs and vaccines.

**1. Performance Comparison:**

* **Cumulative Return:** PFE -15.14% vs. S&P 500 (VOO) 141.71%
* **Performance Gap:** -156.85 (relative to historical range)
* **Alpha and Beta Analysis:**
    * The company has shown fluctuating alpha values, indicating varying performance against the market, with positive alpha in 2016-2018 and 2020-2022, but negative alpha in other periods.
    * The beta values consistently hover around 0.7-0.8, suggesting the stock is moderately volatile compared to the market.

**2. Recent Price Movement:**

* **Closing Price:** 27.46 (Last-market: 26.84)
* **5-day Moving Average:** 27.73
* **20-day Moving Average:** 28.62
* **60-day Moving Average:** 28.91
* **Current Price:** PFE is currently trading below its 5, 20, and 60-day moving averages, indicating a potential downtrend. 

**3. Technical Indicators:**

* **RSI:** 24.12 - Suggests the stock is oversold.
* **PPO:** -0.5 - Indicates a bearish momentum.
* **Delta_Previous_Relative_Divergence:** -0.4 (-) - Short-term downtrend.
* **Expected Return:** 0.0 -  Long-term (2+ years) expected return is currently projected to be in line with the S&P 500.

**4. Recent Earnings and Outlook:**

* **Earnings:**
    * **2024-10-29:** EPS: 1.06 (Expected: 0.614) -  Beat expectations
    * **2024-07-30:** EPS: 0.6 (Expected: 0.458) - Beat expectations
    * **2024-05-01:** EPS: 0.82 (Expected: 0.516) - Beat expectations
    * **2024-01-30:** EPS: 0.1 (Expected: -0.19) -  Beat expectations
    * **2023-10-31:** EPS: -0.17 (Expected: -0.32) - Beat expectations

* **Analysis:** Pfizer has consistently exceeded earnings expectations in recent quarters. This suggests strong underlying performance and potential for continued growth. 

**5. Financial Information:**

* **Revenue and Profitability:** Revenue has been steadily increasing, with strong profit margins, indicating healthy business performance.
* **Capital and Profitability:** The company shows positive equity with fluctuating ROE (Return on Equity) demonstrating variable profitability in recent quarters.

**6. News and Recent Issues:**

* **Recent Earnings Reports:** Pfizer reported strong earnings in the past few quarters, exceeding analysts' expectations. This positive performance was driven by continued strong sales of its flagship products, including COVID-19 vaccines and treatments.
* **Analyst Opinions:** Analysts generally maintain a positive outlook on Pfizer, citing its strong track record of innovation and growth. However, some analysts note potential concerns about the company's dependence on a few key products and the future of its COVID-19 business.

**7. Comprehensive Analysis:**

PFE has shown some weakness in its recent stock performance, trading below moving averages and showing oversold conditions. Despite this, the company has consistently beat earnings expectations, indicating underlying strength and potential for growth. The company's strong financial performance and positive analyst opinions contribute to a cautiously optimistic outlook. The stock is currently in line with market expectations for long-term returns.  

**8. Recommendation:**

While PFE is currently facing some headwinds, the company's strong financial performance and positive earnings outlook suggest it could be a valuable addition to a diversified portfolio for long-term investors. However, investors should closely monitor the stock's performance and remain aware of the potential risks associated with its dependence on a few key products. 

Please note: This is a general analysis based on the provided information. It is not financial advice and does not constitute a recommendation to buy or sell any securities. Investors should conduct their own thorough research and consult with a qualified financial advisor before making any investment decisions. 
